Company Overview and News

0
Star Media's board sees new director, another director resigns

2018-08-11 theedgemarkets
KUALA LUMPUR (Aug 10): Former Tradewinds Plantation Bhd chief executive officer (CEO) Chan Seng Fatt will join the board of directors of Star Media Group Bhd effective tomorrow (Aug 11).
6084 9318 0806 VPGLF BSMAF 1818

0
Malaysia must brace for short-term pain

2018-06-10 thestar.com.my
“I think foreign investors are actively exploring investment opportunities. But generally there is still a wait-and-see attitude and an air of uncertainty over how the new government will go about its programme of improvements,” Cheah(filepic) told StarBiz
0806 VPGLF

5
The Power of Diversity

2018-05-02 scmp
In a global economy, companies that seek to grow beyond the local market need to employ a pool of talent representing diverse points of view and the knowledge to succeed. Diversity can be a competitive differentiator.
FOSUF UOVEF 0656 UOVEY 0806 VPGLF FOSUY U11

5
From the Dean

2018-05-02 scmp
The principle that people should be hired for positions, and promoted or rewarded, solely on the basis of their talents and performance, and not because of their gender, ethnic origins or other functionally irrelevant demographic attributes, is widely accepted today. But beyond a sense of being on the right side of social progress, does employing a more diverse workforce boost performance?
FOSUF UOVEF 0656 UOVEY 0806 VPGLF FOSUY U11

5
Inside Track

2018-05-02 scmp
An internship can provide the all-important building blocks for developing a future career. The process can include learning through practical experience, gaining insights into industry trends, and forming the first threads of a professional network. Chairman of Value Partners Group, Dato’ Cheah Cheng Hye, and CEO - Greater China of the United Overseas Bank (UOB), Mrs Christine Ip, explain how internships can provide a valuable learning curve for students and make a big difference when they enter the job market.
UOVEF UOVEY 0806 VPGLF U11

2
Value Partners Group, Ltd. 2017 Q4 - Results - Earnings Call Slides

2018-03-12 seekingalpha - 2
The following slide deck was published by Value Partners Group, Ltd. in conjunction with their 2017 Q4 earnings call.
0806 VPGLF

Related Articles

REPH: Recro Pharma Analysis and Research Report

1h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

1h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...